Clinical trials: sponsored by Daewoong Pharmaceutical Co. LTD.
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Autoimmune Diseases
Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers
The safety and tolerability of single and multiple administration of DWP212525
- Trial name
- NCT06736587
- Testing
- DWP212525 XXmg
- Where
- South Korea
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy
Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults
Drug-Drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 With DWP16001 in Healthy Adults
- Trial name
- NCT07213310
- Testing
- DWP16001, DWC202511, DWC202512
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Volunteers
Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions
This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fasting conditions.
- Trial name
- NCT07260851
- Testing
- DWJ1622, DWC202313, DWC202314
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Volunteers
Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.
This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.
- Trial name
- NCT07267221
- Testing
- DWJ1622, DWC202313, DWC202314
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Subjects
PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers
A bioequivalence study comparing DWJ1445 and DWC202506 in healthy adults
- Trial name
- NCT07256600
- Testing
- DWJ1445, DWC202506
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Subjects
PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers
PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers
- Trial name
- NCT07144176
- Testing
- DWJ1511, DWC202501
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Lines
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
- Trial name
- NCT07013279
- Testing
- DWP712 inj., Botox® 100 Units
- Where
- South Korea
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Colonoscopy
Efficacy and Safety of DWJ1609 for Bowel Cleansing Before Colonoscopy;
Phase of Development : III Sponsor : DAEWOONG PHARMACEUTICAL Study Sites and Principal Investigator : Dong ll Park M.D. Ph.D , Gastroenterology Kangbuk Samsung Hospital and other 6 study sites Study Period : From the protocol…
- Trial name
- NCT06062030
- Testing
- DWJ1609, DWC202304
- Where
- South Korea
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy
The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects
A Phase 1, First-in-human, Randomized, Double-blind, Placebo controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DWP213388 after Single and Multiple Ascending Oral Dose Administration in…
- Trial name
- NCT05607589
- Testing
- DWP213388
- Volunteers
- healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy
Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults
- Trial name
- DW_DWP16001112 (NCT06644404)
- Testing
- DWP16001 0.3mg, DWC202407 1,000mg, DWC202408 2mg
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Volunteers
Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315
This study aims to evaluate the safety and pharmacokinetic characteristics after administration of DWJ1589 and DWC202315 in healty adult volunteers.
- Trial name
- NCT06592495
- Testing
- Period 1, Period 2, Period 3
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Volunteers
Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers
A randomized, double-blind, placebo-controlled, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous DWP14012 injection in healthy volunteers
- Trial name
- NCT06508645
- Testing
- DWP14012 injection
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Erosive Gastroesophageal Reflux Disease
to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection
to evaluate the safety/tolerability and pharmacokinetics, and pharmacodynamics after intravenous DWP14012 injection in healthy participants
- Trial name
- NCT06437951
- Testing
- Fexuprazan Injection, Fexuprazan Injection_part 2, Fexuprazan Injection_part 3
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function
This study aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of DWP16001 in subjects with hepatic impairment compared with subjects with normal hepatic function.
- Trial name
- NCT05747664
- Testing
- DWP16001
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy
Pharmacokinetics and Safety, Tolerability of DWJ211in Healthy Volunteers
This is a randomized, open-label, parallel design Phase I clinical trial to evaluate the safety/tolerability and pharmacokinetic of DWJ211 in healthy volunteers
- Trial name
- NCT04159961
- Testing
- DWJ211
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Submental Fat
Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
Evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat
- Trial name
- SMF (NCT03946592)
- Testing
- Normal saline, DWJ211
- Where
- South Korea
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Treatment for Submental Fat
Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat
- Trial name
- SMF (NCT03224117)
- Testing
- DWJ211, Normal saline
- Where
- 3 sites in South Korea
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Lines
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
- Trial name
- NCT06212960
- Testing
- DWP712, BOTOX®
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Drug Drug Interaction
Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects
This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.
- Trial name
- NCT06119958
- Testing
- DWC202313, DWC202314
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.